Name | Tyrphostin AG1433 |
---|---|
Synonyms | MFCD03426524 |
Description | Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
Flk-1:9.3 μM (IC50) PDGFRβ:5 μM (IC50) |
In Vitro | Tyrphostin AG1433 (0.1-100 μM; 72 hours; GB8B cells) treatment induces moderate cytotoxicity in glioblastoma cells[1]. Cell Viability Assay[1] Cell Line: GB8B cells Concentration: 0.1 μM, 1 μM, 5 μM, 10 μM, 20 μM, 30 μM, 50 μM, 60 μM, 100 μM Incubation Time: 72 hours Result: Induced significant cell death in GB8B cells in a concentration-dependent manner. |
In Vivo | Chorion allantoic membrane (CAM) assays are used to determine the effects of the Flk-i inhibitors on angiogenesis. Tyrphostin AG1433 (SU1433) is prepared in methylcellulose pellets and applies to the CAMs of 4-6-day-old chicken embryos. Tyrphostin AG1433 prevents the formation of new yessels under the pellets[2]. |
References |
Molecular Formula | C16H14N2O2 |
---|---|
Molecular Weight | 266.29 |